Manufacturer profile
Bausch & Lomb Incorporated
Pharmaceutical company4 products tracked
4
products tracked
73,260
total reports
23
recalls on record
47.8%
serious overall
Products
showing 4 of 4
| Product | Approved | Reports ↓ | Top signal | Recalls |
|---|---|---|---|---|
| 2001 | 27,882 | Intraocular pressure increased | 9 | |
| 2001 | 27,882 | Intraocular pressure increased | 10 | |
| 2016 | 16,017 | Instillation site reaction | 4 | |
| — | 1,479 | Polypoidal choroidal vasculopathy | 0 |
Recall history · 14 on record
| Date | Class | Reason | Firm |
|---|---|---|---|
| Mar 5, 2026 | II | Lack of Assurance of Sterility | Apotex Corp. |
| Sep 5, 2025 | II | Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns | Apotex Corp. |
| May 28, 2025 | II | Lack of Assurance of Sterility | Apotex Corp. |
| Mar 1, 2023 | II | Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility. | Apotex Corp. |
| May 10, 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| May 10, 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| May 10, 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| May 10, 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| Jun 4, 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| Jun 4, 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| Jun 4, 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| Mar 19, 2019 | II | cGMP Deviations | Allergan Sales, LLC |
| Oct 19, 2017 | III | Failed Impurities/Degradation Specifications. | Allergan Sales, LLC |
| Jun 23, 2017 | II | Incorrect/Undeclared Excipient; non-pharmaceutical grade PEG 40 Castor Oil was used due to a mislabeling by the supplier | ImprimisRx CA, Inc., dba ImprimisRx |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.
Registration status
Some products from Bausch & Lomb Incorporated are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.